Notis McConarty Edward cut its holdings in Celgene Co. (NASDAQ:CELG) by 21.0% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 11,620 shares of the biopharmaceutical company’s stock after selling 3,087 shares during the period. Notis McConarty Edward’s holdings in Celgene were worth $1,153,000 at the end of the most recent reporting period.
Several other institutional investors have also bought and sold shares of CELG. First Trust Advisors LP boosted its stake in shares of Celgene by 1.7% during the 3rd quarter. First Trust Advisors LP now owns 523,581 shares of the biopharmaceutical company’s stock worth $51,992,000 after purchasing an additional 8,650 shares during the period. Daiwa Securities Group Inc. boosted its stake in shares of Celgene by 0.3% during the 3rd quarter. Daiwa Securities Group Inc. now owns 48,322 shares of the biopharmaceutical company’s stock worth $4,799,000 after purchasing an additional 145 shares during the period. Manchester Capital Management LLC boosted its stake in shares of Celgene by 6.5% during the 3rd quarter. Manchester Capital Management LLC now owns 10,404 shares of the biopharmaceutical company’s stock worth $1,033,000 after purchasing an additional 636 shares during the period. Donaldson Capital Management LLC purchased a new position in shares of Celgene during the 3rd quarter worth about $355,000. Finally, Bartlett & Co. LLC boosted its stake in shares of Celgene by 143.2% during the 3rd quarter. Bartlett & Co. LLC now owns 535 shares of the biopharmaceutical company’s stock worth $53,000 after purchasing an additional 315 shares during the period. Hedge funds and other institutional investors own 72.31% of the company’s stock.
In other Celgene news, insider Terrie Curran sold 11,338 shares of the business’s stock in a transaction dated Wednesday, September 18th. The shares were sold at an average price of $98.27, for a total value of $1,114,185.26. Following the completion of the sale, the insider now directly owns 13,493 shares of the company’s stock, valued at approximately $1,325,957.11. The transaction was disclosed in a filing with the SEC, which is available through this link. 0.39% of the stock is owned by insiders.
Celgene stock traded up $0.54 during trading hours on Friday, hitting $109.54. The company had a trading volume of 5,706,800 shares, compared to its average volume of 6,764,924. The firm has a market cap of $76.64 billion, a P/E ratio of 14.39, a P/E/G ratio of 0.51 and a beta of 1.41. The company has a debt-to-equity ratio of 1.51, a quick ratio of 2.80 and a current ratio of 2.89. Celgene Co. has a 1 year low of $58.59 and a 1 year high of $109.75. The company has a 50-day moving average price of $102.54 and a two-hundred day moving average price of $96.76.
Celgene (NASDAQ:CELG) last released its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported $2.99 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.70 by $0.29. The company had revenue of $4.52 billion during the quarter, compared to analysts’ expectations of $4.39 billion. Celgene had a net margin of 34.63% and a return on equity of 78.15%. The firm’s quarterly revenue was up 16.1% on a year-over-year basis. During the same period in the previous year, the company earned $2.29 EPS. As a group, equities research analysts anticipate that Celgene Co. will post 10.7 EPS for the current year.
A number of research firms recently commented on CELG. Standpoint Research cut shares of Celgene from a “buy” rating to a “hold” rating in a research note on Friday, November 1st. Robert W. Baird cut shares of Celgene from an “outperform” rating to a “neutral” rating and set a $101.00 price target for the company. in a research note on Friday, November 1st. Cowen reaffirmed a “hold” rating and set a $102.00 price target on shares of Celgene in a research note on Tuesday, July 30th. Wells Fargo & Co set a $110.00 price target on shares of Celgene and gave the stock a “hold” rating in a research note on Friday, November 1st. Finally, BidaskClub raised shares of Celgene from a “buy” rating to a “strong-buy” rating in a research note on Friday, November 1st. One analyst has rated the stock with a sell rating, nineteen have assigned a hold rating, one has assigned a buy rating and one has issued a strong buy rating to the company’s stock. Celgene has an average rating of “Hold” and a consensus target price of $97.31.
Celgene Company Profile
Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers.
Featured Article: What causes a stock to be most active?
Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.